Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Exposure to DMT may delay disability accumulation in primary progressive MS
Key clinical point: Longer exposure to DMT may delay time to EDSS 7 in patients with primary progressive MS.
Major finding: Compared with shorter exposure, longer exposure entailed a significantly lower risk of EDSS 7 (adjusted hazard ratio, 0.73).
Study details: A retrospective review of data for 1,214 patients with primary progressive MS in an Italian registry.
Disclosures: Study funding was not reported. Dr. Fonderico had no relevant disclosures.
Citation:
Fonderico M et al. ECTRIMS 2020. Abstract PS05.03.